利福喷丁与利福平治疗肺结核的疗效及安全性对比  

Comparison of efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis

作　　者：于娟 YU Juan(Haicheng Tuberculosis Control Institute,Haicheng 114200,China)

机构地区：[1]海城市结核病防治所药局,114200

出　　处：《中国现代药物应用》2020年第16期110-112,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨利福喷丁与利福平治疗肺结核的疗效及安全性。方法122例肺结核患者,利用抽签分组法分为研究组和对照组,各61例。研究组采用利福喷丁进行治疗,对照组采用利福平进行治疗。对比两组患者治疗效果、不良反应发生情况、痰菌转阴率、病变吸收率、空洞闭合率。结果研究组的临床治疗总有效率95.08%高于对照组的77.05%,差异有统计学意义(P<0.05)。研究组的痰菌转阴率93.44%、病变吸收率91.80%、空洞闭合率90.16%均高于对照组的75.41%、77.05%、72.13%,差异有统计学意义(P<0.05)。研究组的不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论在肺结核的临床治疗过程中可以将利福喷丁作为治疗的首选药物,进而保证临床治疗的有效性和安全性。Objective To discuss the efficacy and safety of rifapentine and rifampicin in the treatment of pulmonary tuberculosis.Methods A total of 122 patients with pulmonary tuberculosis were divided into research group and control group by lottery method,with 61 cases in each group.The research group was treated by rifapentine,and the control group was treated by rifampicin.The therapeutic effect,occurrence of adverse reactions,sputum negative-conversion rate,lesion absorption rate and cavity closure rate were compared between the two groups.Results The total effective rate of clinical treatment 95.08%of the research group was higher than that of the control group 77.05%,and the difference was statistically significant(P<0.05).The sputum negativeconversion rate 93.44%,lesion absorption rate 91.80%and cavity closure rate 90.16%of the research group was higher than that of the control group 75.41%,77.05%and 72.13%,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of the research group was lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion In the clinical treatment of pulmonary tuberculosis,rifapentin can be used as the first choice to ensure the effectiveness and safety of clinical treatment.

关 键 词：肺结核 利福喷丁 利福平 安全性 

分 类 号：R521[医药卫生—内科学]